摘要
目的探讨奥氮平与喹硫平治疗老年期痴呆伴精神行为症状患者的I临床疗效和安全性。方法将60例老年痴呆伴精神行为症状患者随机分两组，每组30例。奥氮平组口服奥氮平治疗，喹硫平组口服喹硫平治疗，观察8周。采用阿尔茨海默病病理行为评定量表、Cohen-Mansfield激惹性问卷评定患者的精神行为症状及激越行为，采用副反应量表评定不良反应。结果治疗1周末奥氮平组阿尔茨海默病病理行为评定量表、CohenMansfield激惹性问卷评分显著低于喹硫平组（P〈0.05）；治疗8周末奥氮平组显效率为60．0％、总有效率为83．3％，喹硫平组分别为63．3％、80．0％，两组比较差异无显著性（P〉0.05）；两组副反应量表评分、不良反应发生率比较差异均无显著性（P〉0．05）。结论奥氮平与喹硫平治疗老年期痴呆伴精神行为症状患者疗效均显著，安全性高，但奥氮平起效更快。
Objective To compare the efficacy and safety of olanzapine vs. quetiapine in the treatment of behavioral and psychological symptoms （BPS） of senile dementia （SD）. Methods Sixty SD patients with BPS were randomly divided into two groups of 30 ones each taking orally olanzapine or quetiapine for 8 weeks. Behavioral and psychological symptoms and agitation behavior were assessed with the Behavioral Pathology in Alzheimer＇s Disease Rating Scale （BEHAVE-AD） and Cohen Mansfield Agitation Inventory （CMAI） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results The BE HAVE-AD and CMAI score were significantly lower in olanzapine than quetiapine group at the end of the 1st week （P〈0.05） ; at the end of the 8th week obvious and total effective rate were respectively 60.0% and 83.3% in olanzapine and 63.3% and 80.0% in quetiapine group, which showed no significant differences （P〈0.05） ; there were no significant differences in the TESS score and ioncidences if adverse reactions be- tween two groups （P〉0.05）. Conclusion Both olanzapine and qtletiapine have an evident effect and high- er safety, but the former takes effect more rapidly in the treatment of SD patients with BPS.
出处
《临床心身疾病杂志》
CAS
2013年第3期229-231,共3页
Journal of Clinical Psychosomatic Diseases
